NYSE ARCA | ETF
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| ISRG | Intuitive Surgical Inc | Healthcare | Medical Instruments & Supplies | 9.49% |
| SRPT | Sarepta Therapeutics Inc | Healthcare | Biotechnology | 8.61% |
| CI | Cigna Corp | Healthcare | Healthcare Plans | 6.48% |
| PCT | Purecycle Technologies Holdings Corp | Industrials | Pollution & Treatment Controls | 4.87% |
| MDT | Medtronic PLC | Healthcare | Medical Devices | 4.65% |
| ALGN | Align Technology Inc | Healthcare | Medical Devices | 4.64% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 4.62% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 4.6% |
| SWAV | Shockwave Medical Inc | Healthcare | Medical Devices | 3.58% |
| TMO | Thermo Fisher Scientific Inc | Healthcare | Diagnostics & Research | 3.53% |
| RPRX | Royalty Pharma Plc | Healthcare | Biotechnology | 3.31% |
| EXAS | EXACT Sciences Corporation | Healthcare | Diagnostics & Research | 3.25% |
| VRTX | Vertex Pharmaceuticals Inc | Healthcare | Biotechnology | 3.22% |
| BSX | Boston Scientific Corp | Healthcare | Medical Devices | 3.14% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 2.82% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.55% |
| ZBH | Zimmer Biomet Holdings Inc | Healthcare | Medical Devices | 2.5% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 2.16% |
| AVTR | Avantor Inc | Basic Materials | Specialty Chemicals | 2.06% |
| BDX | Becton Dickinson and Company | Healthcare | Medical Instruments & Supplies | 2.05% |
Under normal circumstances, the fund will invest at least 80% of its assets (plus any borrowings for investment purposes) in securities of U.S. health care companies. The fund adviser defines health care companies as companies included in the Global Industry Classification Standard health care sector. The fund will typically invest in 50 " 100 health care companies. The adviser generally seeks investments in companies that are developing new and effective medicines, as well as companies whose business models reduce costs or improve quality in health care systems.